By Armen Hareyan on April 15, 2008 - 8:26am 
for eMaxHealth
for eMaxHealthGeneNews reported positive performance results from a large validation study of a six-gene biomarker panel for the assessment of a patient's current risk for colorectal cancer. This panel forms the basis of the Company's lead product, ColonSentry, which is planned for launch in Canada in the third quarter of 2008 as a laboratory-developed test.
The validation study confirmed (p less than 0.05) that the panel was able to stratify a population with average risk for colorectal cancer into three groups:
-
Source:
GeneNews Limited eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
